This chart is temporarily missing...
This chart is temporarily missing...

Learn about the benefits of proven design>

* XIENCE V has demonstrated statistical superiority in the primary endpoints of SPIRIT IV, SPIRIT III and SPIRIT II in target lesion failure, in-segment late loss and in-stent late loss respectively. Source: SPIRIT IV 1-year results, Gregg Stone, TCT 2009 and XIENCE V IFU. TAXUS Express was the control in SPIRIT IV.
References
  1. XIENCE V IFU.
  2. XIENCE V IFU.
  3. Source: SPIRIT IV 1-Year results, Gregg Stone, TCT 2009.
Control stents: SPIRIT II (TAXUS Express 73% of lesions, TAXUS Liberte 27% of lesions), SPIRIT III (TAXUS Express), SPIRIT IV (TAXUS Express)